Glucagon-Like Peptide 1
Novo Nordisk’s Wegovy Pill Launches Strongly Amid Analyst Caution
Wegovy pill; Novo Nordisk; FDA approval; oral GLP-1; obesity drug; Eli Lilly competition
Corxel Pharmaceuticals Raises $287M Series D1 to Advance Oral GLP-1 Obesity Drug CX11
Corxel Pharmaceuticals; Series D1; GLP-1; CX11; obesity drug; funding; Vincentage
Teva Launches First Generic GLP-1 for Weight Loss Amid Ongoing Market Developments
generic GLP-1; Teva; liraglutide; Saxenda; FDA approval; weight loss drugs
FDA Requests Eli Lilly and Novo Nordisk to Remove Suicide Warnings from GLP-1 Drug Labels
FDA; GLP-1; suicide warnings; Eli Lilly; Novo Nordisk; Wegovy; Zepbound; Saxenda
Novo Nordisk Refocuses on Diabetes and Obesity to Expand GLP-1 Market at JPM26
Novo Nordisk; diabetes; obesity; GLP-1; JPM26; Mike Doustdar; Wegovy pill; semaglutide
Roche’s Patent License Deal with Structure Therapeutics for CT-996 Obesity Drug
Roche; Structure Therapeutics; patent license; CT-996; obesity drug; Genentech; GLP-1
Novo Nordisk Launches Wegovy Pill in the US with Broad Availability
Novo Nordisk; Wegovy pill; US launch; January 2026; oral GLP-1; weight loss
Novo Nordisk Wins FDA Approval for First Oral GLP-1 Wegovy Pill in Obesity Treatment
Novo Nordisk; Wegovy pill; FDA approval; oral semaglutide; obesity treatment; GLP-1
Lilly seeks rapid FDA approval for oral GLP-1 orforglipron after positive obesity “switching” study
Eli Lilly; orforglipron; oral GLP-1; FDA approval; national priority review voucher; ATTAIN-MAINTAIN trial; obesity treatment; weight maintenance; Zepbound; Wegovy; injectable incretins; Phase 3 trial
Exclusive: Compounding giant Empower Pharmacy cuts hundreds of staff, stops New Jersey operations
Empower Pharmacy; compounding pharmacy; layoffs; job cuts; New Jersey operations; East Windsor facility; manufacturing shutdown; outsourcing facility; FDA inspection; Form 483; compounded GLP-1 drugs; workforce reduction